A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Clinical trial NCT04075396 · COMPLETED
Trial details
- NCT number
- NCT04075396
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-16
- Primary completion
- 2021-01-08
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.